Emmaus Life Sciences, Inc.

Emmaus Life Sciences, Inc. is a commercial-stage biopharmaceutical company dedicated to the discovery, development, marketing, and sale of innovative treatments for rare and orphan diseases. The company’s flagship product, Endari, is an L-glutamine oral powder designed to reduce acute complications associated with sickle cell disease in adults and pediatric patients aged five and older. Emmaus has also developed a portfolio of pipeline products targeting conditions such as diverticulosis, blood cancers, and osteoarthritis, as well as research tools for cellular measurement and cartilage replacement technologies. Operating internationally, Emmaus Life Sciences collaborates with entities like Kainos Medicine, Inc., securing rights to proprietary therapies such as the IRAK4 inhibitor for prospective cancer treatments. Headquartered in Torrance, California and founded in 2000, the company plays a significant role in the biotechnology sector by addressing unmet needs in underserved patient populations, particularly within hematological and genetic disorders.